Portrait Peng Wu

Wu Lab


Selected publications from 2019 to 2024 (*corresponding author; #equally contributed authors):


Georg Goebel, Nicole Giannino, Philipp Lampe, Xiaqiu Qiu, Jeffrey Schloßhauer, Jochen Imig, Sonja Sievers, Peng Wu*.
Profiling Cellular Morphological Changes Induced by Dual-targeting PROTACs of Aurora Kinase and RNA-binding Protein YTHDF2. ChemBioChem. 2024

(Invited submission for the special issue “Advances in Chemical Probing Concepts for Chemical Biology Applications”)



Ruth Brenk, Peng Wu and Maria Duca*.
Introduction to the themed collection on ‘Targeting RNA with small molecules’. RSC Med. Chem. 2024



Yang Liu#, Georg L. Goebel#, Laurin Kanis, Oguz Hastürk, Claus Kemker, and Peng Wu*.
Aminothiazolone Inhibitors Disrupt the Protein–RNA Interaction of METTL16 and Modulate the m6A RNA Modification. JACS Au 2024


Lydia Borgelt, Lisa Hohnen, Jakob S. Pallesen, Pascal Hommen, Georg L. Goebel, Francesco Bosica, Yang Liu, Gavin O’Mahony*, and  Peng Wu*.
N-Biphenyl Pyrrolinones and Dibenzofurans as RNA-Binding Protein LIN28 Inhibitors Disrupting the LIN28–Let-7 Interaction. ACS Med. Chem. Lett. 2023


L. Borgelt and P. Wu*. Targeting Ribonucleases with Small Molecules and Bifunctional Molecules. ACS Chem. Biol. 2023  
doi: 10.1002/cbic.202300376
(Invited submission, “Nucleic Acid Regulation” special issue)


P. Hommen, J. Hwang, F. Huang, L. Borgelt, L. Hohnen, P. Wu*.
Chromenopyrazole–peptide conjugates as small-molecule based inhibitors disrupting the protein–RNA interaction of LIN28–let-7. ChemBioChem 2023, accepted.

(for the special issue of “ChemBioTalents 2022/2023”)

L. Borgelt#, F. Huang#, L. Hohnen, X. Qiu, G. Goebel, P. Hommen, P. Wu*.
Spirocyclic chromenopyrazole inhibitors disrupting the interaction between the RNA-binding protein LIN28 and let-7. ChemBioChem 2023,accepted.
 doi: 10.1002/cbic.202300168.

(Invited submission for the special issue of “ChemBioTalents 2022/2023”)

J. Hwang#, H. Haacke#, L. Borgelt, X. Qiu, R. Gasper, P. Wu*.
Rational design and evaluation of 2-((pyrrol-2-yl)methylene)thiophen-4-ones as RNase L inhibitors. Eur. J. Med. Chem. 2023, accepted,
see more >

A. Avathan Veettil, J. Kirchhoff, L. Brieger, C. Strohmann, P. Wu*.
Petasis sequence reactions for the scaffold-diverse synthesis of bioactive polycyclic small molecules. ACS Omega. 2023, 8 (1), 1168–1181.
doi: 10.1021/acsomega.2c06585

L. Borgelt#, N. Haacke#, P. Lampe#, X. Qiu, R. Gasper, D. Schiller, D. Summerer, S. Sievers, P. Wu*.
Small molecule screening of ribonuclease L binders for RNA degradation. Biomed. Pharmacother. 2022, 154, 113589.
DOI: 10.1016/j.biopha.2022.113589.

G. Goebel#, X, Qiu#, P. Wu*.
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. Trends Pharmacol. Sci. 2022, 43 (10), 866–881.
DOI: 10.1016/j.tips.2022.04.006.

C. Hui, Y. Liu, M. Jiang, P. Wu*.
Cyclobutane-containing scaffolds in bioactive small molecules. Trends Chem. 2022, 4 (8), 677–681.
DOI: 10.1016/j.trechm.2022.04.006.

J. Hwang#, X, Qiu#, L. Borgelt, N. Haacke, L. Kanis, S. Petroulia, R. Gasper, D. Schiller, P. Lampe, S. Sievers, J. Imig, P. Wu*.

Synthesis and evaluation of RNase L-binding 2-aminothiophenes as anticancer agents. Bioorg. Med. Chem. 2022, 58, 116653.
DOI: 10.1016/j.bmc.2022.116653.

G. L. Goebel#, L. Hohnen#, L. Borgelt, P. Hommen, X. Qiu, H. Lightfoot, P. Wu*.
Small molecules with tetrahydroquinoline-containing Povarov scaffolds as inhibitors disrupting the Protein–RNA Interaction of LIN28–Let-7. Eur. J. Med. Chem. 2022, 228, 114014.,
DOI: 10.1016/j.ejmech.2021.114014

L. Borgelt#, F. Li#, P. Hommen#, P. Lampe#, J. Hwang, G. L. Goebel, S. Sievers, P. Wu*. Trisubstituted Pyrrolinones as Small-Molecule Inhibitors Disrupting the Protein–RNA Interaction of LIN28 and Let-7. ACS Med. Chem. Lett. 2021,
DOI: 10.1021/acsmedchemlett.0c00546.
(Invited submission for the special issue of “RNA: Opening New Doors in Medicinal Chemistry”)

P. Wu*.
Inhibition of RNA-Binding Proteins with Small Molecules. Nat. Rev. Chem. 2020, 4, 441-458.
DOI: 10.1038/s41570-020-0201-4.

J. Hwang, L. Borgelt, P. Wu*.
Multicomponent Petasis Reaction for the Synthesis of Functionalized 2-Aminothiophenes and Thienodiazepines. ACS Comb. Sci. 2020, 22, 495-499.
DOI: 10.1021/acscombsci.0c00173.

S. Siriwardena#, D. Godage#, V. Shoba#, S. Lai#, M. Shi, P. Wu, S. Chaudhary, S. L. Schreiber, A. Choudhary*.
Phosphorylation-Inducing Chimeric Small Molecules. J. Am. Chem. Soc. 2020, 142, 33, 14052-14057.

P. Wu*, M. Givskov, T. E. Nielsen*. 
Reactivity and Synthetic Applications of Multicomponent Petasis Reactions. Chem. Rev. 2019, 119, 11245-11290.
DOI: 10.1021/acs.chemrev.9b00214.

P. Wu#, W. E. Bjorn-Yoshimoto#, M. Staudt, A. A. Jensen*, L. Bunch*.
Identification and structure-activity relationship study of imidazo[1,2-α]pyridine-3-amines – as first selective inhibitors of excitatory amino acid transporter subtype 3 (EAAT3). ACS Chem NeuroSci. 2019, 10, 4414-4429.
DOI: 10.1021/acschemneuro.9b00447.

B. Maji, S. Gangopadhyay#, M. Lee#, M. Shi#, P. Wu#, R. heler, B. Mok, D. Lim, S. Siriwardena, B. Paul, V. Dančík, A. Vetere, M. Mesleh, L. A. Marraffini, D. R. Liu, R. A. Clemons, B. K. Wagner, A. Choudhary*.
A high-throughput platform to identify inhibitors of CRISPR-Cas9. Cell 2019, 177, 1067-1079.E19.
DOI: 10.1016/j.cell.2019.04.009

Before 2019 and Full List of Publications  >>>



3.    P. Wu*, P. Diner, L. Bunch, Chapter 3. The Screening and Design of Allosteric Kinase Inhibitors
       Kinase Drug Discovery: Modern Approaches
       Edited by R. A. Ward and F. Goldberg
       Royal Society of Chemistry, London, 2019, Pp. 34-60
       DOI: 10.1039/9781788013093-00034


2.    P. Wu*, A. Choudhary*, Chapter II.2.
       Successful Drug Discovery, Volume 3
       Edited by J. Fischer, C. Klein and W. E. Childers
       Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2018, Pp. 65-93
       DOI: 10.1002/9783527808694.ch3


1.    P. Wu*, M. Givskov, T. E. Nielsen*, Chapter 2.4.2
       Drug Selectivity – An Evolving Concept in Drug Discovery
       Edited by N. Handler and H. Buschmann
       Book in Series Methods and Principles in Medicinal Chemistry, ISSN: 1865-0562    
       Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 2017, Pp. 33-53
       DOI: 10.1002/9783527674381.ch2




Go to Editor View